Document is current
Any future updates will be listed below
-
Authors
Scalia, Gabriele https://orcid.org/0000-0003-3305-9220
Rutherford, Steven T. https://orcid.org/0000-0002-4758-4248
Lu, Ziqing
Buchholz, Kerry R. https://orcid.org/0000-0001-9419-0076
Skelton, Nicholas
Chuang, Kangway
Diamant, Nathaniel
Hütter, Jan-Christian
Luescher, Jerome-Maxim
Miu, Anh
Blaney, Jeff
Gendelev, Leo
Skippington, Elizabeth
Zynda, Greg https://orcid.org/0000-0003-4992-9614
Dickson, Nia
Koziarski, Micha https://orcid.org/0000-0001-7707-9640
Bengio, Yoshua https://orcid.org/0000-0002-9322-3515
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Tan, Man-Wah
Biancalani, Tommaso https://orcid.org/0000-0001-9104-9755
- License Information
-
More Information
Article History
Received: 31 August 2024
Accepted: 13 August 2025
First Online: 24 October 2025
Competing interests
: G.S., S.T.R., Z.L., K.R.B., N.S., K.C., J-C.H., J.B., L.G., E.S., A.R, M.-W.T. and T.B. are employees of Genentech and shareholders of Roche. Y.B. is an advisor for Recursion Pharmaceuticals. A.R. is a cofounder and equity holder of Immunitas and, until July 31, 2020, was a scientific advisory board member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. The other authors declare no competing interests.
